| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 3. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | alteplase (Actilyse®) |
| Formulation | 10 mg, 20 mg and 50 mg powder and solvent for solution for injection/infusion |
| Reference number | 472 |
| Indication | Fibrinolytic treatment of acute ischaemic stroke. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques (licence extension of three hour time limit) |
| Company | Boehringer Ingelheim Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 27/04/2010 |